Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Innovative medical technology is trying to solve the problem of getting people to take their medicine, but its cost and its unfamiliarity has blocked widespread use, the Washington Post reports.
Driving the news: The first digital therapy to be approved by the Food and Drug Administration, Abilify MyCite, isn't on the market because of providers' and insurers' reservations about the product.
- Abilify is an old drug used to treat schizophrenia and other mental illnesses. The new product is the same pill but with an electronic tracking component added, which transmits a signal when it comes into contact with stomach acid.
- Eventually, doctors can view the data collected to monitor whether a patient is taking his or her medicine — serious information for schizophrenia patients.
- Abilify MyCite costs $1,650 a month.
The big picture: The collision of drugs and medical devices with Silicon Valley has resulted in apps to help treat numerous health care conditions, and there are studies underway for more digital pills to treat cancer and other diseases.
- But the cost-effectiveness of these new technologies hasn't yet been proven, and until if and when it is, that's a huge barrier to uptake.
- "I think that these technologies have a lot of potential benefits, but it's going to be a question of evidence — that they can demonstrate value to patients and payers," former FDA Commissioner Scott Gottlieb told the Post.
Go deeper: A blind spot for medical AI